Monitoring oral propranolol for infantile hemangiomata. Issue 11 (11th October 2022)

• Record Type: Journal Article
• Authors: Bar, Jonathan; Bar‐Ilan, Efrat; Cleper, Roxana; Sprecher, Eli; Samuelov, Liat; Mashiah, Jacob
• Is Part Of: Dermatologic therapy. Volume 35:Issue 11(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-10-11
• Subjects: beta‐blockers -- hemangiona -- infantile hemangiomas -- propranolol -- therapy‐systemic; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.15870
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Treating infantile hemangiomas with oral propranolol may be initiated in accordance with various protocols some require hospitalization. However, different adverse events have been reported during treatment, thus it is of special importance to find a protocol which is both safe and feasible. We performed a retrospective cohort study of all cases of infantile hemangiomas treated with oral propranolol at our institute between January 2010 and February 2020. Pretreatment evaluation consisted of pediatric cardiologist evaluation including electrocardiography and echocardiography. The propranolol starting dosage was 0.5 mg/kg bid; 2 weeks later the dosage was escalated to 1 mg/kg bid. During the initiation and escalation visits, heart rate and blood pressure were measured before and every hour for a total of 3 h, and blood glucose level was measured within the first hour of treatment. A total of 131 children were treated during the study period. Scalp, facial and genital region infantile hemangiomas were more prevalent in regard to their relative body surface area. No symptomatic bradycardia, hypotension, hypoglycemia, or any other adverse events were documented; few patients had asymptomatic bradycardia and hypotension, which were more common in infants below 6‐months of age. Only one patient had asymptomatic hypoglycemia, not requiring any intervention. Initiation and escalation of propranolol treatment for infantile hemangiomas proved to be safe, and without symptomatic adverse effects. However, considering the young age of the patients and the possible asymptomatic adverse reactions, we recommend the following simple protocol as presented, for pretreatment evaluation and short monitoring during treatment initiation and dose escalation.